Other hypertrophic cardiomyopathy
Methodology & AI Transparency ⓘ
Other hypertrophic cardiomyopathy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Heart & Cardiovascular Disease diagnostic criteria (I42.2), workup for Other hypertrophic cardiomyopathy integrates hemodynamic risk profiling [Other hypertrophic cardiomyopathy I42.2] with evidence-graded therapy tailored to NT-proBNP [Other hypertrophic cardiomyopathy I42.2] response.
- 2 Real-world patient consensus: Federal ICD-10-CM code I42.2 categorizes Other hypertrophic cardiomyopathy under Heart & Cardiovascular Disease.
- 3 Typical cash cost range: Differential triage of Other hypertrophic cardiomyopathy (I42.2) utilizes hemodynamic risk profiling [Other hypertrophic cardiomyopathy I42.2].
- 4 Top reported side effects / signs: Longitudinal Other hypertrophic cardiomyopathy monitoring tracks NT-proBNP [Other hypertrophic cardiomyopathy I42.2] toward < 100 pg/mL (I42.2).
Ask our AI Specialists anything about Other hypertrophic cardiomyopathy
What Is Other hypertrophic cardiomyopathy?
Under Heart & Cardiovascular Disease diagnostic criteria (I42.2), workup for Other hypertrophic cardiomyopathy integrates hemodynamic risk profiling [Other hypertrophic cardiomyopathy I42.2] with evidence-graded therapy tailored to NT-proBNP [Other hypertrophic cardiomyopathy I42.2] response.
Pathophysiology, Underlying Causes & Clinical Presentation
In Other hypertrophic cardiomyopathy (I42.2), physiological disruption stems from subendocardial perfusion deficits [Other hypertrophic cardiomyopathy I42.2], informing Heart & Cardiovascular Disease protocols that track High-Sensitivity Troponin I [Other hypertrophic cardiomyopathy I42.2] (< 14 ng/L (I42.2)).
Common Symptoms & Clinical Signs
- • Presentation of Other hypertrophic cardiomyopathy (I42.2): shortness of breath in Other hypertrophic cardiomyopathy (I42.2: when climbing stairs)
- • Secondary Other hypertrophic cardiomyopathy clinical sign: palpitations, skipped beats, in Other hypertrophic cardiomyopathy (I42.2: or irregular resting)
- • Symptom flares in Other hypertrophic cardiomyopathy correlating with NT-proBNP [Other hypertrophic cardiomyopathy I42.2] deviation outside < 100 pg/mL (I42.2)
- • Functional heart & vascular impact requiring hemodynamic risk profiling [Other hypertrophic cardiomyopathy I42.2] evaluation (I42.2)
Other hypertrophic cardiomyopathy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I42.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: NT-proBNP [Other hypertrophic cardiomyopathy I42.2] | < 100 pg/mL (I42.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Other hypertrophic cardiomyopathy I42.2] | < 14 ng/L (I42.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Other hypertrophic cardiomyopathy I42.2] | < 70 mg/dL (I42.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other hypertrophic cardiomyopathy
Treatment selection for Other hypertrophic cardiomyopathy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other hypertrophic cardiomyopathy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| GLP-1RA vs. Placebo: Which Works Better for Heart failure and mildly reduced or preserved ejection fraction? GLP-1RA reduce HF exacerbations and can play a role in reducing hospitalizations, improving patient's functional status, and significantly impacting the global healthcare burden of HF. International journal of cardiology • 2025-11-01 • Meta-Analysis | N = 4,474 | 99/100 | PMID 40623630 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
Other hypertrophic cardiomyopathy Patient Community & “People Like Me” Threads
Filter Other hypertrophic cardiomyopathy community threads and patient logs by age, biological sex, dosage, and treatment duration.